首页 › 基金 › Carlyle Group Inc. › PHAT
Carlyle Group Inc. 对 PHAT 的持仓历史
PHATHOM PHARMACEUTICALS INC · 医疗保健
Carlyle Group Inc. 在 Q3 2026 的 13F 申报中披露持有 PHAT(PHATHOM PHARMACEUTICALS INC)3,496,808 股,市值约 US$25.5M,约占其申报组合的 0.31%,在其申报持仓中市值排名第 3 位。 Carlyle Group Inc. 最近 13 个申报季度中有 13 个季度披露了 PHAT 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Carlyle Group Inc. 对 PHAT 的持仓演变
Carlyle Group Inc. 于 Q3 2023 首次披露 PHAT 持仓:3,496,808 股(约 US$36.2M)。 该持仓在 Q3 2024 达到峰值 3,496,808 股,市值约 US$63.2M。 在 13 次申报中,Carlyle Group Inc. 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 3,496,808 股、市值约 US$25.5M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 3.50M | $36.19M | 新进 |
| Q4 2023 | 3.50M | $31.93M | 持有 |
| Q1 2024 | 3.50M | $37.10M | 持有 |
| Q2 2024 | 3.50M | $35.84M | 持有 |
| Q3 2024 | 3.50M | $63.19M | 持有 |
| Q4 2024 | 3.50M | $28.39M | 持有 |
| Q1 2025 | 3.50M | $21.92M | 持有 |
| Q2 2025 | 3.50M | $33.53M | 持有 |
| Q3 2025 | 3.50M | $41.05M | 持有 |
| Q4 2025 | 3.50M | $57.98M | 持有 |
| Q1 2026 | 3.50M | $38.85M | 持有 |
| Q2 2026 | 3.50M | $37.94M | 持有 |
| Q3 2026 | 3.50M | $25.53M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 PHAT 与 13F 数据
PHAT(PHATHOM PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 29 只申报持有 PHAT,申报仓位最大的包括:Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$54.5M), NEA Management Company, LLC (US$21.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 PHAT 的基金
- Frazier Life Sciences Management, L.P. 12.47M 股 · $135.26M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 7.46M 股 · $54.49M · Q3 2026
- NEA Management Company, LLC 1.96M 股 · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M 股 · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M 股 · $13.74M · Q3 2026
- Propel Bio Management, LLC 1.11M 股 · $8.07M · Q3 2026
- EcoR1 Capital, LLC 625.00K 股 · $6.78M · Q2 2026
更多关于 Carlyle Group Inc.
常见问题
How long has Carlyle Group Inc. held PHAT?
Carlyle Group Inc. has disclosed PHAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Carlyle Group Inc.'s current position in PHAT?
As of Q3 2026, Carlyle Group Inc. holds 3.50M shares of PHAT (PHATHOM PHARMACEUTICALS INC), valued at $25.53M, representing 0.31% of its reported portfolio and ranking #3.
Has Carlyle Group Inc. been buying or selling PHAT?
In the latest 13F filing (Q3 2026), Carlyle Group Inc. held unchanged its position in PHAT. The position peaked in Q3 2024 at 3.50M shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, NEA Management Company, LLC, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.